Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05384496
Title Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

mucosal melanoma

Therapies

Axitinib + Ipilimumab + Nivolumab

Axitinib + Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.